To investigate the impact of tomotherapy on the dose delivered to the lungs and other normal tissues.
Material and Methods
From February 2008 to May 2009, 35 patients with stage IIIA/IIIB non-small cell lung cancer were treated with helical tomotherapy at the S. Camillo-Forlanini Hospital. For our study we selected 20 patients who underwent chemotherapy followed by sequential radiotherapy. The planning target volume was delineated using planning CT scan and FDG-PET. The mean prescribed radiation dose was 67.5 Gy delivered in 30 fractions at a dose of 2.25 Gy per fraction.
Results
Median follow-up was 12.3 months. All patients developed acute esophageal toxicity, 15 of RTOG grade 1 and 5 of RTOG grade 2. At first follow-up 15 patients presented stable disease or partial response, 4 patients presented complete response, and 1 patient presented disease progression.
Conclusions
Helical tomotherapy is useful to achieve dose-per-fraction escalation without increasing the treatment-related morbidity. Our results applying dose escalation were encouraging considering that we delivered doses that may be difficult to achieve with 3-dimensional treatments with no excessive complication rates.
Le ChevalierT., ArriagadaR., QuoixE., RuffieP., MartinM., TarayreM., Lacombe-TerrierM.J., DouillardJ.Y., LaplancheA.: Radiotherapy alone vs combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.J Natl Cancer Inst, 83: 417–423, 1991.
2.
CoxJ.D., AzarniaN., ByhardtR.W., ShinK.H., EmamiB., PerezC.A.: N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group.Int J Radiat Oncol Biol Phys, 20: 7–12, 1991.
3.
HazukaM.B., TurrisiAT3rd, LutzS.T., MartelM.K., Ten HakenR.K., StrawdermanM., BoremaP.L., LichterA.S.: Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis.Int J Radiat Oncol Biol Phys, 27: 273–284, 1993.
MackieT.R., HolmesT., SwerdloffS., ReckwerdtP., DeasyJ.O., YangJ., PaliwalB., KinsellaT.: Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy.Med Phys, 20: 1709–1719, 1993.
6.
MehtaM., ScrimgerR., MackieR., PaliwalB., ChappellR., FowlerJ.: A new approach to dose escalation in non-small-cell lung cancer.Int J Radiat Oncol Biol Phys, 49: 23–33, 2001.
7.
AldridgeJ.S., HarariP.M., ReckwerdtP.J., OliveraG.H., ToméW., FinkM.B., MackieT.R.: Development of conformal avoidance tomotherapy in the treatment of head and neck cancer.Radiat Oncol Biol Phys,45(suppl 1): 245, 1999.
WoelR.T., MunleyM.T., HollisD., FanM., BentelG., AnscherM.S., ShafmanT., ColemanR.E., JaszczakR.J., MarksL.B.: The time course of radiation therapy-induced reductions in regional perfusion: A prospective study with >5 years of follow-up.Int J Radiat Oncol Biol Phys, 52: 58–67, 2002.
11.
De JaegerK., SeppenwooldeY., BoersmaL.J., MullerS.H., BaasP., BelderbosJ.S., LebesqueJ.V.: Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer.Int J Radiat Oncol Biol Phys, 55: 1331–1340, 2003.
12.
KronT., GrigorovG., YuE., WongE., ChenJ., KimB., LockM., RodriguesG., BattisitaJ.: Optimisation of radiotherapy delivery and planning time for helical tomotherapy by means of pre-calculated planning parameters.Med Phys, 30: 1938, 2003.
13.
AshamallaH., RaflaS., ParikhK., MokhtarB., GoswamiG., KambamS., Abdel-DayemH., GuirguisA., RossP., EvolaA.: The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.Int J Radiat Oncol Biol Phys, 63: 1016–1023, 2005.
14.
GrillsI.S., YanD., BlackQ.C., WongC.Y., MartinezA.A., KestinL.L.: Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer.Int J Radiat Oncol Biol Phys, 67: 709–719, 2007.
15.
RamseyC., LangenK., KupelianP.A., ScaperothD.D., MeeksS.L.: A technique for adaptive image-guided helical tomotherapy for lung cancer.Int J Radiat Oncol Biol Phys, 64: 1237–1244, 2006.
16.
ScrimgerR.A., ToméW.A., OliveraG.H., ReckwerdtP.J., MehtaM.P., FowlerJ.F.: Reduction in radiation dose to lung and other normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional field arrangements.Am J Clin Oncol, 26: 70–78, 2003.
17.
PerezC.A., BauerM., EdelsteinS., GillespieB.W., BirchR.: Impact of tumor control on survival in carcinoma of the lung treated with irradiation.Int J Radiat Oncol Biol Phys, 12: 539–547, 1986.
18.
SaundersM., DischeS., BarrettA., HarveyA., GibsonD., ParmarM.: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.Lancet, 350: 161–165, 1997.
19.
SauseW., KolesarP., TaylorS.IV, JohnsonD., LivingstonR., KomakiR., EmamiB., CurranW.Jr., ByhardtR., DarA.R., TurrisiA3rd: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.Chest, 117: 358–364, 2000.
20.
HoriotJ.C., BontempsP., van den BogaertW., Le FurR., van den WeijngaertD., BollaM., BernierJ., LusinchiA., StuschkeM., Lopez-TorrecillaJ., BeggA.C., PierartM., ColletteL.: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.Radiother Oncol, 44: 111–121, 1997.
